What one share of Pyxis Oncology holds
Pyxis Oncology is a clinical-stage oncology company advancing a development strategy focused on addressing unmet medical needs in patients with solid tumors with an immediate focus on head and neck squamous cell carcinoma (HNSCC).
Pyxis Oncology’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Profit | −$1.40 |
|---|---|
| Cash and investments | $0.52 |
| Book value | $0.18 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2020 | — | −$12.45 | $1.44 | −$11.22 | — | −$12.13 |
| 2021 | — | −$8.95 | $0.06 | −$4.22 | — | — |
| 2022 | — | −$3.65 | $0.19 | −$2.90 | — | $4.60 |
| 2023 | — | −$1.85 | $0.17 | −$1.94 | — | $2.81 |
| 2024 | $0.28 | −$1.32 | $0.00 | −$0.99 | — | $2.01 |
| 2025 | $0.22 | −$1.28 | $0.00 | −$1.02 | — | $0.85 |
Common questions about Pyxis Oncology
How much does one share of Pyxis Oncology earn?
Over the last 12 months, Pyxis Oncology lost $1.40 for each share.
Does Pyxis Oncology pay a dividend?
Pyxis Oncology didn’t pay a dividend over the last 12 months, according to its SEC filings.
What is Pyxis Oncology’s book value per share?
Pyxis Oncology’s book value is $0.18 per share: what would be left for each share if it sold everything at the values on its books and paid every debt, as of June 30, 2026.
How much cash and debt does each share of Pyxis Oncology have?
Each share of Pyxis Oncology has $0.52 of cash and investments, as of June 30, 2026.
Has Pyxis Oncology bought back shares?
Pyxis Oncology’s share count rose about 5930% from 2020 to 2025. That dilution means each share owns a smaller slice of the company.
From its SEC filings. For education only, not investment advice. New to these words? See the StockSlicer glossary.